Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common antioxidant shield kidneys from a powerful antibiotic?

NCT ID NCT07668141

Disease control Sponsor: Helwan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking alpha-lipoic acid, an antioxidant, can protect the kidneys of hospitalized patients who need the strong antibiotic colistin. Colistin can cause kidney damage, and researchers want to see if this supplement lowers that risk. The trial will involve 88 adults with multidrug-resistant infections and will use a urine biomarker to detect early kidney injury.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
alpha-lipoic acid
What this could lead to
If it works, this could offer a simple way to protect kidneys during colistin treatment, reducing the risk of acute kidney injury.
What could go wrong
This is a small, early-phase trial with only 88 participants. The benefit seen in animal studies may not translate to humans, and alpha-lipoic acid may not prevent kidney damage in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 88 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients who receive intravenous colistin and had positive cultures of multidrug resistant gram negative bacteria. * Patients who receive colistin for at least 3 days during their treatment. Exclusion Criteria: * Patients who receive inhaled colistin. * Patients who had AKI at baseline * chronic kidney disease patients on regular hemodialysis. * Renal transplant patients * Concurrent use of other nephrotoxic drugs e.g. vancomycin, gentamicin, amikacin and amphotericin B. * Concurrent use of other antioxidants e.g. vitamin C, vitamin E and N-acetyl cysteine. * Patients are not willing to participate in the study. * Patients with any missed doses of colistin and or alpha-lipoic acid. * Patients with incomplete medical data * Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nephrotoxicity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nephrotoxicity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 6th October Hospital-Dokki-General Authority for Health Insurance Organization

    Giza, Egypt

  • Al-Haram Hospital

    Giza, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.